Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DARANIDE vs DIAMOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Edema due to congestive heart failure,Drug-induced edema,Glaucoma (adjunctive therapy)
Treatment of elevated intraocular pressure in open-angle glaucoma,Secondary glaucoma,Preoperative reduction of intraocular pressure in acute angle-closure glaucoma,Adjunctive treatment of edema due to congestive heart failure,Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Altitude sickness (acute mountain sickness) prophylaxis and treatment
50 mg orally once or twice daily; maximum 100 mg/day.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Not extensively metabolized; excreted unchanged in urine.
Metabolized primarily via hydrolysis to acetazolamide (active) and then further to inactive metabolites; minimal hepatic metabolism.
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; p H-dependent; alkaline urine increases elimination.
~90% bound, primarily to albumin.
~90% bound, primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
0.2-0.3 L/kg. Clinical meaning: Confined primarily to extracellular fluid; low Vd indicates minimal tissue distribution.
0.2 L/kg; distributes into total body water; concentrates in red blood cells, kidney, and eye.
Oral: 75-85% (tablet).
Oral: ~100% (well absorbed, but food may delay absorption).
GFR 10-50 m L/min: 50 mg every 12-24 hours; GFR <10 m L/min: 50 mg every 24-48 hours; not effective if GFR <10 m L/min.
GFR 10-50 m L/min: 250 mg every 12 hours; GFR <10 m L/min: avoid use
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Not established; use not recommended in children.
Glaucoma: 8-15 mg/kg/day orally divided every 6-8 hours; Edema: 5 mg/kg IV or IM every 6 hours
Start at 25 mg once daily; monitor renal function and electrolyte balance due to increased risk of adverse effects.
Start at lowest dose (250 mg orally every 12 hours); monitor renal function and electrolytes due to increased risk of metabolic acidosis and hypokalemia
None.
No FDA black box warning.
May cause drowsiness, confusion, or paresthesias,Monitor electrolytes and renal function,Can cause metabolic acidosis,Use caution in patients with hepatic impairment or cirrhosis
May cause metabolic acidosis; use caution in patients with pulmonary obstruction or emphysema.,Sulfonamide derivative; may cause hypersensitivity reactions including Stevens-Johnson syndrome.,Contraindicated in severe hepatic or renal dysfunction; may precipitate hepatic encephalopathy.,Monitor serum electrolytes and blood counts during prolonged therapy.,May impair mental alertness; caution when driving or operating machinery.
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal or hepatic dysfunction,Hypokalemia,Hyponatremia,Metabolic acidosis,Adrenal insufficiency
Hypersensitivity to acetazolamide or any sulfonamide,Severe hepatic disease or cirrhosis,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Hyperchloremic acidosis,Adrenal insufficiency
No specific food interactions reported. However, maintain adequate hydration to reduce risk of kidney stones. Avoid excessive salt intake if edema is present. Grapefruit juice is not known to interact.
Avoid high-dose vitamin C (may increase risk of kidney stones). No other significant food interactions.
Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of electrolyte disturbances and acidosis in neonate; avoid use unless benefit outweighs risk.
Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposure may be associated with increased risk of congenital anomalies, particularly of the limbs and neural tube. Risk likely low but consider alternatives in first trimester. In second and third trimesters, no clear fetal toxicity but monitor for potential electrolyte imbalances and acidosis.
Contraindicated in breastfeeding. Excreted in breast milk; M/P ratio not established. Potential for serious adverse effects in infant (metabolic acidosis, electrolyte imbalance).
Acetazolamide excreted into breast milk; M/P ratio approximately 0.25 for total acetazolamide, but for free drug may be higher. Milk levels low (about 10% of maternal serum). No reported adverse effects in infants; caution in neonates with renal or hepatic impairment, or those at risk for electrolyte disturbances.
No standard dose adjustments; increased renal clearance in pregnancy may lower drug levels, but empirical dose changes are not recommended due to risk of metabolic acidosis. Use lowest effective dose if unavoidable.
Pregnancy-induced pharmacokinetic changes (increased renal clearance, expanded plasma volume) may require dose adjustments. No specific guidelines; monitor clinical response and serum electrolyte levels. Consider starting at lower doses (e.g., 250 mg daily) and titrate based on response and tolerability. In severe conditions (e.g., glaucoma), maintain effective dose but monitor closely for electrolyte disturbances and metabolic acidosis.
DARANIDE (dichlorphenamide) is a carbonic anhydrase inhibitor used for chronic open-angle glaucoma and secondary glaucoma. Monitor for metabolic acidosis, especially in patients with renal impairment. Can cause hypokalemia; check serum potassium periodically. Avoid concurrent use with high-dose salicylates due to risk of metabolic acidosis and salicylate toxicity. May cause drowsiness or confusion; caution in elderly. Not a first-line agent; reserved for patients intolerant or unresponsive to other therapies.
DIAMOX (acetazolamide) is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and edema. It can cause metabolic acidosis; monitor electrolytes. Avoid in severe hepatic or renal impairment. Use with caution in patients with sulfonamide allergy.
Take exactly as prescribed, usually 3-4 times daily with food to reduce GI upset.,May cause tingling or numbness in fingers, toes, or mouth; this is common and usually harmless.,Drink plenty of fluids to prevent kidney stones; report painful urination or blood in urine.,Avoid aspirin or high-dose salicylates; check with doctor before taking any OTC pain relievers.,Regular eye exams and blood tests (potassium, bicarbonate) are necessary.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Tell your doctor if you have kidney disease, liver disease, or electrolyte imbalance.,Notify your doctor if you experience weakness, weight loss, confusion, or rapid breathing.
Take exactly as prescribed; do not skip doses.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DARANIDE vs DIAMOX, answered by our medical review team.
DARANIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.. DIAMOX is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DARANIDE and DIAMOX depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DARANIDE is: 50 mg orally once or twice daily; maximum 100 mg/day.. The standard adult dose of DIAMOX is: 250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DARANIDE and DIAMOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DARANIDE is classified as Category C. Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of . DIAMOX is classified as Category C. Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.